Abstract
A critical appraisal and clinical application of Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol. 2009 Aug;43(7):680-5. doi: 10.1097/MCG.0b013e318188947c
DOI
10.22237/crp/1484092920
Recommended Citation
Szafranski J. Combination octreotide, midodrine, and albumin may improve survival in patients with hepatorenal syndrome, but the evidence is weak. Clin. Res. Prac. 2017;3(1):eP1136. doi: 10.22237/crp/1484092920
Included in
Hepatology Commons, Medical Education Commons, Nephrology Commons, Translational Medical Research Commons
